Skip to main content
SRZN
NASDAQ Life Sciences

Surrozen Reports Deepened Q1 Net Loss of $127.5M Amidst Patent Challenge, Secures $26.9M from ATM

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$34.13
Mkt Cap
$392.041M
52W Low
$5.9
52W High
$35
52W Position info
478% above low
Off High info
2.5% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

SRZN has more than doubled off its 52-week low of $5.9.

Summary

Surrozen, Inc. reported a significantly increased net loss of $127.5 million for Q1 2026, primarily due to non-cash fair value adjustments, alongside a 34% rise in cash used in operations. The company also disclosed a patent challenge from Merck and continued to raise capital through its ATM program, securing $26.9 million.


Key Events · Earnings and Guidance · SRZN

  • Deepened Net Loss

    Q1 2026 net loss surged to $127.5 million, up from $27.0 million in Q1 2025, largely driven by non-cash fair value adjustments of tranche and warrant liabilities.

  • Increased Cash Burn

    Cash used in operating activities rose to $12.5 million in Q1 2026, compared to $9.3 million in the prior year period.

  • Patent Challenge from Merck

    Merck filed a post-grant review petition in February 2026 challenging a key patent (U.S. Patent No. 12,297,278) related to Surrozen's SWAP platform.

  • Capital Infusion from ATM and Warrants

    The company raised $26.9 million in net proceeds from its 2025 ATM program and $3.3 million from warrant exercises during Q1 2026. An additional $0.8 million from warrant exercises was received in April 2026.


Analysis · SRZN · Life Sciences

Surrozen's Q1 2026 results highlight significant financial challenges, with a substantial net loss primarily stemming from non-cash fair value adjustments of complex financial instruments. The increase in cash used in operations indicates a higher burn rate, underscoring the company's ongoing need for capital. While the successful utilization of the ATM program and warrant exercises, along with the $5.0 million milestone payment from Boehringer Ingelheim, provide crucial liquidity, the new patent challenge from Merck introduces a material legal and intellectual property risk. The company's future liquidity is also contingent on the second tranche of the 2025 PIPE, tied to FDA clearance for SZN-8141 by October 2026. Investors should monitor the progress of the patent dispute and the SZN-8141 IND application, as these events will significantly impact the company's financial stability and long-term prospects.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SRZN was trading at $34.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $392M. The 52-week trading range was $5.90 to $35.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SRZN - Latest Insights

SRZN
Nov 09, 2026, 4:59 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $32.00 info
Change: $0 (0%) info
Market Cap: $376.114M info
SRZN
Nov 09, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $32.00 info
Change: $0 (0%) info
Market Cap: $376.114M info
SRZN
Nov 09, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $32.00
Real-time Price: $32.00 info
Change: $0 (0%) info
Market Cap: $376.114M info
SRZN
Oct 20, 2026, 4:59 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $25.14
Real-time Price: $32.00 info
Change: +$6.86 (+27%) info
Market Cap: $376.114M info
SRZN
Oct 02, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.13
Real-time Price: $32.00 info
Change: +$1.87 (+6%) info
Market Cap: $376.114M info